The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.
S. R. Alberts
Consultant or Advisory Role - Merck Serono (U)
Research Funding - Bristol-Myers Squibb
S. N. Thibodeau
No relevant relationships to disclose
D. J. Sargent
No relevant relationships to disclose
M. R. Mahoney
No relevant relationships to disclose
F. Sinicrope
No relevant relationships to disclose
A. F. Shields
Consultant or Advisory Role - Bristol-Myers Squibb
E. Chan
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech; ImClone Systems; Pfizer; Sanofi
Research Funding - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Idera; ImClone Systems; Lilly; Merck; MethylGene; Pfizer
R. M. Goldberg
Consultant or Advisory Role - Genentech; Lilly
Research Funding - Abbott Laboratories; Amgen; Bayer; Bristol-Myers Squibb; Genentech; Sanofi
S. Gill
Consultant or Advisory Role - Bristol-Myers Squibb; Sanofi
M. S. Kahlenberg
Employment or Leadership Position - Genentech
J. T. Quesenberry
No relevant relationships to disclose
T. C. Smyrk
No relevant relationships to disclose
A. Grothey
No relevant relationships to disclose
S. G. Nair
No relevant relationships to disclose